 |
 |

Topiramate-Associated Secondary Angle-Closure Glaucoma: A Case Series
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
We read with great interest the article by Sankar et al1
and report a case series of secondary acute angle-closure glaucoma associated
with topiramate (Topamax; Ortho-McNeil Pharmaceutical, Inc, Raritan, NJ) and
submitted to the Food and Drug Administration's Center for Drug and Evaluation
Research Adverse Events Reporting System between April 1999 and July 2001.
The case series includes 19 patients, 2 of whom were described by Sankar et
al. The patients were predominantly female (89%) with a mean age of 36.5 years
(age range, 5-53 years). Indications included epilepsy (n = 5), depression
(n = 5), neuropathic pain (n = 2), migraine (n = 2), bipolar disorder (n =
2), weight loss (n = 1), and unknown (n = 2). When doses were reported (53%
of cases), they were within the recommended range. Time to symptom onset was
reported in 15 cases and typically occurred soon after starting topiramate;
the . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Peripheral Iridoplasty Efficacy in Refractory Topiramate-Associated Bilateral Acute Angle-Closure Glaucoma
Zalta and Smith
Arch Ophthalmol 2008;126:1603-1605.
FULL TEXT
|